Core Insights - The chairman of Dana Biotech, Zhou Zeqi, emphasizes the importance of long-term investment in core technology for sustainable development in the biopharmaceutical industry [1] - Dana Biotech, founded in 2014, has become a leader in early diagnosis of fungal diseases in China and is set to be the first IVD company listed on the Beijing Stock Exchange [1][2] - The company has developed a "5G+ Joint Detection Scheme" to enhance the precision of diagnosing various pathogenic infections [1][3] Company Development - Zhou Zeqi returned to China in 2008 to contribute to the biopharmaceutical sector, identifying a significant gap in the diagnosis of pathogenic microorganisms, particularly fungal diseases [1][2] - The first core product, derived from horseshoe crab blood, allows for rapid differentiation between fungal and bacterial infections, significantly reducing diagnosis time from several days to as little as 15 minutes [2][3] - The market for invasive fungal disease diagnostic reagents in China is projected to grow from 240 million yuan in 2018 to 3.03 billion yuan by 2030, with a compound annual growth rate of 23.5% [2] Product Innovation - Dana Biotech has diversified its product offerings, including antigen-antibody tests and molecular diagnostics, and has established a robust product matrix [3][4] - The company has obtained 91 domestic and international patents and 79 medical device registrations, with unique products registered in China [4][5] - Annual R&D investment exceeds 30 million yuan, accounting for over 10% of total revenue, supporting the development of six core technology platforms [4][5] Future Prospects - The company plans to use funds from its IPO for the construction of a new headquarters and further R&D, focusing on invasive fungal infections and AI applications in diagnostics [6][7] - AI technology is expected to enhance diagnostic efficiency and accuracy, providing multidimensional diagnostic results to assist physicians [6][7] - Dana Biotech aims to establish itself as a leader in the fungal diagnostics industry, aspiring to set international standards [7]